Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nuvalent (NUVL – Research Report), NewAmsterdam Pharma Company (NAMS – Research Report) and Marinus (MRNS – Research Report).
Nuvalent (NUVL)
Leerink Partners analyst Christopher Liu maintained a Hold rating on Nuvalent yesterday and set a price target of $69.00. The company’s shares closed last Monday at $72.80, close to its 52-week high of $80.94.
According to TipRanks.com, Liu is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $79.50 average price target.
See the top stocks recommended by analysts >>
NewAmsterdam Pharma Company (NAMS)
In a report issued on January 4, Roanna Ruiz from Leerink Partners maintained a Buy rating on NewAmsterdam Pharma Company. The company’s shares closed last Monday at $12.13.
According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $24.50.
Marinus (MRNS)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Marinus on January 4 and set a price target of $20.00. The company’s shares closed last Monday at $11.21, close to its 52-week high of $11.25.
According to TipRanks.com, Skorney is a 1-star analyst with an average return of
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $19.44, representing an 80.2% upside. In a report issued on January 3, RBC Capital also maintained a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NUVL:
